NTRK2 and neuroblastoma: Lately, these methods have been coupled with strategies targeting specific oncogenic drivers of neuroblastoma, including MYCN, ALK, and TrkB, that are associated with HR-NB, and novel treatment strategies are currently being investigated [19].